Literature DB >> 11022932

Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL)

R Nitsch, I Bechmann, R A Deisz, D Haas, T N Lehmann, U Wendling, F Zipp.   

Abstract

Cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL) was believed to occur exclusively in tumour cells, suggesting that this drug is safe to use as an antitumour therapy. Concerns were raised, however, when cultured normal human hepatocytes were shown to be susceptible to TRAIL. Here we report that TRAIL induces apoptosis in the human brain. Our finding therefore argues against the use of TRAIL for therapy of human brain tumours. However, neuroinflammatory T cells that express TRAIL might induce apoptosis of brain tissue, indicating a potential target for treatment of multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11022932     DOI: 10.1016/S0140-6736(00)02659-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  68 in total

1.  B lymphocytes are resistant to death receptor 5-induced apoptosis.

Authors:  Roslyn N Crowder; Hong Zhao; W Winn Chatham; Tong Zhou; Robert H Carter
Journal:  Clin Immunol       Date:  2011-01-28       Impact factor: 3.969

Review 2.  [Neurological complications of neurooncological therapy].

Authors:  U Herrlinger; J P Steinbach
Journal:  Nervenarzt       Date:  2010-08       Impact factor: 1.214

3.  Elevated serum TRAIL levels in scleroderma patients and its possible association with pulmonary involvement.

Authors:  Noha A Azab; Hanaa M Rady; Samar A Marzouk
Journal:  Clin Rheumatol       Date:  2012-06-23       Impact factor: 2.980

4.  APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo.

Authors:  Günter Eisele; Patrick Roth; Kathy Hasenbach; Steffen Aulwurm; Fabian Wolpert; Ghazaleh Tabatabai; Wolfgang Wick; Michael Weller
Journal:  Neuro Oncol       Date:  2010-12-22       Impact factor: 12.300

Review 5.  Failed central nervous system regeneration: a downside of immune privilege?

Authors:  Ingo Bechmann
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

6.  Multiple sclerosis: death receptor expression and oligodendrocyte apoptosis in established lesions.

Authors:  Barbara Cannella; Stefanie Gaupp; Kakuri M Omari; Cedric S Raine
Journal:  J Neuroimmunol       Date:  2007-07-05       Impact factor: 3.478

7.  TRAIL limits excessive host immune responses in bacterial meningitis.

Authors:  Olaf Hoffmann; Josef Priller; Timour Prozorovski; Ulf Schulze-Topphoff; Nevena Baeva; Jan D Lunemann; Orhan Aktas; Cordula Mahrhofer; Sarah Stricker; Frauke Zipp; Joerg R Weber
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

8.  TNF-related apoptosis-inducing ligand level in Alzheimer's disease.

Authors:  Sermin Genc; Mehtap Yuksel Egrilmez; Erdem Yaka; Zahide Cavdar; Leyla Iyilikci; Gorsev Yener; Kursad Genc
Journal:  Neurol Sci       Date:  2009-03-18       Impact factor: 3.307

Review 9.  Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in central nervous system inflammation.

Authors:  Olaf Hoffmann; Frauke Zipp; Joerg R Weber
Journal:  J Mol Med (Berl)       Date:  2009-05-17       Impact factor: 4.599

10.  Assay-based response evaluation in head and neck oncology: requirements for better decision making.

Authors:  Andreas Dietz; Andreas Boehm; Iris-Susanne Horn; Pierre Kruber; Ingo Bechmann; Wojciech Golusinski; Dietger Niederwieser; Ralph Dollner; Torsten W Remmerbach; Christian Wittekind; Stephan Dietzsch; Guido Hildebrandt; Gunnar Wichmann
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-01-06       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.